Antituberculosis agent
The present invention relates to the use in therapy of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof, to pharmaceutically acceptable salts of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione and to pharmaceutical formulations comprising 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof.
1. A method for the treatment of a disease resulting from a mycobacterial infection in a human in need thereof, comprising administering to said human a therapeutically effective amount of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione, or a pharmaceutically acceptable salt thereof.
2. A method for the treatment of a mycobacterial infection in a human in need thereof, the method comprising administering to said human a therapeutically effective amount of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione, or a pharmaceutically acceptable salt thereof.
3. The method according to claim 1 , wherein the mycobacterial infection is a Mycobacterium tuberculosis infection.
4. The method according to claim 1 , wherein the disease is tuberculosis.
5. A salt of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione.
6. A pharmaceutically acceptable salt of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione.
7. The method according to claim 1 , further comprising administering a therapeutically effective amount of a second therapeutic agent.
8. The method according to claim 7 , wherein the second therapeutic agent is selected from the group consisting of isoniazid, rifampin, pyrazinamide, ethambutol, moxifloxacin, rifapentine, clofazimine, bedaquiline, nitroimidazo-oxazine PA-824, delamanid, OPC-167832, an oxazolidinone, EMB analogue SQ109, a benzothiazinone, a dinitrobenzamide, and an antiviral agent.
9. The method according to claim 8 , wherein the oxazolidinone is linezolid, tedizolid, radezolid, sutezolid, or posizolid.
10. The method according to claim 7 , wherein the second therapeutic agent is a therapeutic agent approved for or recommended for the treatment of tuberculosis.
11. A pharmaceutical composition comprising a) 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione, or a pharmaceutically acceptable salt thereof; and b) a pharmaceutically acceptable excipient.
12. The pharmaceutical composition according to claim 11 , further comprising a second therapeutic agent.
13. The pharmaceutical composition according to claim 12 , wherein the second therapeutic agent is selected from the group consisting of isoniazid, rifampin, pyrazinamide, ethambutol, moxifloxacin, rifapentine, clofazimine, bedaquiline, nitroimidazo-oxazine PA-824, delamanid, OPC-167832, an oxazolidinone, EMB analogue SQ109, a benzothiazinone, a dinitrobenzamide, and an antiviral agent.
14. A method of killing a mycobacterium and/or inhibiting the replication of a mycobacterium in a human infected with a mycobacterium , comprising contacting the mycobacterium or treating the human infected with the mycobacterium , with a therapeutically effective amount of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione, or a pharmaceutically acceptable salt thereof.
15. The method according to claim 14 , wherein the mycobacterium is Mycobacterium tuberculosis.
16. The method according to claim 2 , wherein the mycobacterial infection is a Mycobacterium tuberculosis infection.
17. The method according to claim 8 , wherein the antiviral agent is an antiretroviral agent.
18. The pharmaceutical composition according to claim 13 , wherein the antiviral agent is an antiretroviral agent.
19. The pharmaceutical composition according to claim 13 , wherein the oxazolidinone is linezolid, tedizolid, radezolid, sutezolid, or posizolid.
20. The pharmaceutical composition according to claim 12 , wherein the second therapeutic agent is a therapeutic agent approved for or recommended for the treatment of tuberculosis.